THE US Food and Drug
Administration has expanded the
use of Opdivo (nivolumab) for
the treatment of patients with
metastatic non-small cell lung
cancer whose disease progressed
during or after platinum-based
chemotherapy.
Like Keytruda (pembrolizumab),
Opdivo targets the cellular pathway
known as PD-1/PD-L1, with the FDA
saying by blocking the pathway the
drugs may help the body’s immune
system to fight the cancer cells.
Both Opdivo and Keytruda have
been granted accelerated approval
based on a “breakthrough therapy
designation”.The above article was sent to subscribers in Pharmacy Daily's issue from 12 Oct 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Oct 15
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.